The NIH Deal That Parks NIAID Biodefense at the Pentagon

NIH Director Jay Bhattacharya signed a 10-year deal that lets NIAID money pay for Pentagon medical-countermeasure work he has already taken off the institute’s public agenda. The Department of War, the renamed Defense Department, posted the paper on Friday, September 4, a holiday-weekend release about a month after the signatures.

The signed text names no sum and moves no cash on its own. It still opens a decade of NIAID orders that Assistant Secretary Robert Kadlec’s office can turn into contracts, grants, and other transactions for pandemic flu, chemical, biological, radiological, and nuclear threats, and emerging infections.

The Pact Was Signed in August, Posted on Friday

House Democrats had already gone public when the PDF appeared. On September 3, House Appropriations Committee Ranking Member Rosa DeLauro of Connecticut called the pact a secretive attempt to pull billions from the National Institute of Allergy and Infectious Diseases and told the administration to kill it. The Pentagon answered by releasing the agreement and saying any claim of a secret deal was false.

Kadlec signed for the Office of the Assistant Secretary of War for Nuclear Deterrence, Chemical, and Biological Defense Policy and Programs. Bhattacharya signed for NIH. NIH employees have described the push on the Pentagon side as part of a biodefence effort they call Operation Prevailing Edge. The paper itself never uses that name.

FROM THE JANUARY PIVOT TO THE FRIDAY DUMP

1. January 2026: Bhattacharya and NIAID colleagues publish a strategy that drops biodefense as a core focus and argues past pandemic work failed to protect Americans.
2. February 2026: NIAID staff are told to take the phrases “biodefense” and “pandemic preparedness” off the institute’s website.
3. Early August 2026: Bhattacharya and Kadlec sign the interagency agreement under the Economy Act.
4. September 3, 2026: DeLauro says Pentagon officials are trying to divert NIH money and demands a full accounting.
5. September 4, 2026: The Department of War posts the PDF; Bhattacharya defends a project-by-project partnership on X.
6. September 5, 2026: Bhattacharya writes that no funds have gone to the Department of War in fiscal 2026, and none will.

That last line is the part the Friday dump did not carry. It is also the line that lets the administration say, correctly, that the raid has not happened as a wire. The legal path for later orders is already signed.

What the Economy Act Paper Allows

The vehicle is an Economy Act deal under 31 U.S.C. § 1535, plus NIAID’s own statute on infectious-disease and pandemic-pathogen work. NIH is the requesting agency. Kadlec’s office is the servicing agency. NIH is supposed to send money on Fiscal Service Form 7600B before a contract is awarded. The cover paper expires on 30 September 2036 and can be extended if both sides agree.

It does not itself obligate funds. It says so twice, and it warns that no order can break the Antideficiency Act. Either party can walk with at least 180 days’ written notice, or both can tear it up at once. The deal gets a financial review every year and a full review every three years. Press statements are supposed to name both sides and go over five business days early.

WHAT KADLEC’S OFFICE CAN AWARD

• The vehicles: Contracts, grants, cooperative agreements, and other transactions for therapeutics, diagnostics, and personal protective equipment.
• The targets: Future pandemic flu strains, CBRN threats, and other emerging infections, including antivirals, antibacterials, and antitoxins on a list NIH and OASW set together.
• The extras: Rapid-response analysis, white papers for senior leaders, and work to mature detection and protection gear on military timelines.
• The payroll: NIH may pay the expenses of extra OASW staff hired to run the orders.
• The reach: Purchases can go to states, territories, local and tribal governments, and private groups.

NIH keeps final say on product profiles aimed at civilians. OASW keeps final say on profiles built for warfighters, operational settings, and tactical use. NIH also agrees to make civilian data and products available for Department of War biodefense work. Quarterly meetings are mandatory. NIH still has to show that each order fits its legal authorities.

That split is how both claims can be true at once. A White House spokesman, Kush Desai, said NIH is not transferring money to the Pentagon and called it a project-by-project research partnership. An NIH spokesperson said there is no blanket transfer and that every project must sit inside NIH’s mission. The PDF matches those words on day one. It also lets later 7600B orders do the transferring without a new statute.

The Word Biodefense Left NIAID’s Public Map

In a January strategy paper, Bhattacharya and NIAID colleagues argued that the institute’s pandemic-preparedness work “clearly neither prevented the pandemic nor prevented Americans from experiencing among the highest levels of all-cause excess mortality in the developed world during that time.” He later told senators that NIAID was moving away from biodefense toward “conditions that people actually have.” About a third of NIAID’s budget used to sit in biodefense and emerging-pathogen work. A later strategic plan dropped the word “biodefense.”

Eight of NIAID’s ten top officials have been ousted, reassigned, or have stepped down this year. Staff were ordered to scrub biodefense and pandemic-preparedness language from the website in February. The same leadership then signed a decade of NIAID money over to a Pentagon office whose job is chemical and biological defense.

Bhattacharya answered DeLauro on September 4 by saying NIH funds should improve American health, and that the partnership would stay “100% aligned with our public health mission.”

NIH funds should be used to improve the health of Americans.

Far from siphoning money away from research, this partnership between @NIH and @DeptofWar focuses on research projects that will drive discoveries to improve the health of American citizens and members of the military.… https://t.co/QxsOTcWu5b

— Jay Bhattacharya, MD, PhD (@NIHDirector_Jay) September 4, 2026

The next day he went further: “No funds have gone to DOW in FY26, and none will. For FY27, we’ll evaluate opportunities to work together project by project, always in service of NIAID’s strategic vision.” That is a calendar trick as much as a policy. The paper is already in force. The first order can wait until the next fiscal year without a new signature from Congress.

Cole Says Not One Dollar Has Moved

The signed text is silent on how much NIAID cash can ride the pipe. NIH employees described a shift of projects worth hundreds of millions of dollars, with the institute still picking which ones to move before some fiscal 2026 money expires on September 30. People familiar with the talks have put an early figure as high as $2 billion, about a third of NIAID’s $6.6 billion 2026 appropriation. House Democrats used “billions.” Bhattacharya and House Appropriations Chairman Tom Cole of Oklahoma used zero.

Cole said on September 4 that “not one dollar has been transferred from the NIH to the Department of War,” and that Bhattacharya had told him no money would be taken from basic medical research for unrelated Pentagon work. Both men are describing the cover agreement. They are not describing what a 7600B order can do once someone fills one out.

THE MONEY CLAIMS ON THE TABLE

The White House had already tried to shrink NIAID the ordinary way. The White House request of $4.175 billion would have cut the institute hard from the prior year’s level. Lawmakers instead kept it near $6.6 billion. The Economy Act paper is an administrative path around that enacted total, one order at a time, for 10 years.

NIH Is Still Racing a Sept. 30 Grant Clock

Fiscal 2026 money that NIH does not obligate by September 30 returns to the Treasury. The institute has been slow to push grants out the door for a second straight year, after a 43-day shutdown, a delayed budget release, and thinner staff. Public tallies through late June showed slower NIH grant awards in 2026, with grant counts about 25 percent below the 2021 to 2024 pace and dollar outlays roughly 17 percent behind that earlier baseline.

NIH’S 2026 SPEND CLOCK

• The pot: NIH’s fiscal 2026 program level is $47.3 billion, and unused budget authority expires on September 30.
• The pace: Through late June, award counts ran about 25 percent below the 2021 to 2024 baseline.
• The wreckage: As of April 10, HHS had terminated 1,392 NIH grants with $539 million still unspent on the books.
• The workaround: A White House preference for paying multiyear grants as a lump sum means fewer new awards from the same dollars.

A senior NIH official told colleagues the institute wanted projects identified and the arrangement completed before the fiscal year ends and some funds expire. That is the mechanical reason a 10-year servicing deal is useful in September even if Bhattacharya bars a FY26 transfer. Once the pipe exists, an order in October is a paperwork step, not a new negotiation with Congress.

NIAID has not left the field on paper. On September 1 it posted a new funding call for candidate medical countermeasures against radiological, nuclear, or chemical threats, with about $12 million planned for fiscal 2027. The science can stay inside NIH. The new award machinery for “advanced development” now also sits in Kadlec’s shop.

Kadlec’s Office Would Cut the Contracts

Kadlec is not a random Pentagon counterpart. He previously ran preparedness and response at Health and Human Services and had a central role in Operation Warp Speed. He now sits on the receiving side of NIAID orders, with authority to award the same class of advanced products that civilian HHS has long run through the Biomedical Advanced Research and Development Authority. The NIH share of the civilian countermeasure pipeline has been basic science through late-stage trials, with BARDA taking products closer to stockpiles. This pact lets a War Department office do that later-stage work with NIAID cash.

Gigi Gronvall, a biosecurity specialist at the Johns Hopkins Bloomberg School of Public Health, said the military is a poor substitute for NIH’s scientific culture.

The Department of Defense is just not set up to deliver the scientific innovations we have come to expect and rely on from NIH.

Gigi Gronvall, biosecurity specialist, Johns Hopkins Bloomberg School of Public Health

Samuel Bagenstos, who was HHS’s top lawyer until December 2024, said agencies may share money in limited cases. A straight top-up of a military budget from NIH, he said, would not be one of them.

What’s not appropriate or legal is saying, Look, DOD needs money, NIH has money, we’re going to take money and send it to the DOD. That would be illegal, because that would be using funding not to serve the purposes of NIH, but to serve the purposes of DOD.

Samuel Bagenstos, former HHS general counsel

DeLauro tied the timing to the Iran war’s pressure on the Pentagon and said the Department of Defense already has its own, separately funded chemical, biological, and nuclear countermeasure programs. The 2026 Defense budget is roughly $1 trillion. NIAID is $6.6 billion. The disparity is the political fuel. The legal question is whether each future order still serves an NIH purpose, or only a warfighter one.

180 Days’ Notice Is the Only Off-Ramp

Sen. Patty Murray of Washington, the top Democrat on Senate Appropriations, accused the Pentagon of trying to “rob NIH of billions of dollars that Congress provided for medical research so that it can pad the Pentagon’s budget.” DeLauro said the funds were for influenza, malaria, tuberculosis, HIV, Ebola, and other pathogens, “not as extra money for the Department of Defense,” and that “the interagency agreement needs to be terminated immediately.”

This secretive attempt to siphon research funds away from NIH is outrageous. Circumventing Congress to divert money intended to help Americans who are exposed to HIV, influenza, tuberculosis, and other deadly diseases, and directing those funds to the Department of Defense, is beyond the pale.

Rosa DeLauro, House Appropriations ranking member, September 3 statement

Cole called that reading false media and “fearmongering,” and said infectious disease is a national security issue. Bhattacharya’s public file now holds both the partnership defense and the FY26 freeze. Saskia Popescu, an infectious-disease epidemiologist at George Mason University, has warned that pulling the work out of NIAID risks breaking national preparedness into military and civilian pieces that no longer meet.

The louder problem is the pipe. A 10-year unpriced Economy Act vehicle can sit dry through September 30, 2026, and still open on October 1 without another vote. The first Form 7600B is not in public. The paper expires on September 30, 2036, unless a later NIH director uses the 180-day notice, or both sides agree to tear it up sooner.